Latest Articles
Why Is Acrivon Therapeutics Stock Falling Today? - Acrivon Therapeutics (NASDAQ:ACRV) - Benzinga
Why Is Acrivon Therapeutics Stock Falling Today? - Acrivon Therapeutics (NASDAQ:ACRV) Benzinga
Published: Jan. 8, 2026, 7:02 p.m.
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - The Manila Times
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …
Published: Jan. 8, 2026, 12:53 p.m.
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b - GlobeNewswire
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b GlobeNewswire
Published: Jan. 8, 2026, 12:30 p.m.
Onconic Therapeutics wins IND approval for phase 1b–2 gastric cancer trial in Korea - CHOSUNBIZ - Chosunbiz
Onconic Therapeutics wins IND approval for phase 1b–2 gastric cancer trial in Korea - CHOSUNBIZ Chosunbiz
Published: Dec. 17, 2025, 1:04 a.m.
Metri Bio: $5 Million Pre-Seed Secured To Advance Next-Generation Endometriosis Therapeutics - Pulse 2.0
Metri Bio: $5 Million Pre-Seed Secured To Advance Next-Generation Endometriosis Therapeutics Pulse 2.0
Published: Dec. 10, 2025, 12:36 p.m.
Metri Bio raises US$5m for endo therapeutics - FemTech World
Metri Bio raises US$5m for endo therapeutics FemTech World
Published: Dec. 4, 2025, 9:05 a.m.
Metri Bio Raises $5M Pre-Seed to Develop Endometriosis Therapeutics - Femtech Insider
Metri Bio Raises $5M Pre-Seed to Develop Endometriosis Therapeutics Femtech Insider
Published: Dec. 2, 2025, 1:03 p.m.
Acrivon Therapeutics Advances ACR-368 in Phase 2b Trial for Endometrial Cancer and Prepares for Initial Data on ACR-2316 - Quiver Quantitative
Acrivon Therapeutics Advances ACR-368 in Phase 2b Trial for Endometrial Cancer and Prepares for Initial Data on ACR-2316 Quiver Quantitative
Published: Nov. 13, 2025, 9:25 p.m.
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results - The Manila Times
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results The Manila Times
Published: Nov. 5, 2025, 9:37 p.m.
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet? - ts2.tech
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet? ts2.tech
Published: Nov. 3, 2025, 2:12 p.m.
Link copied to clipboard!